Genetic Mutation of 5, 10-Methylenetetrahydrofolate Reductase in the Brain Neoplasms.
- Author:
Jung Yong AHN
1
;
Nam Keun KIM
;
Jin Hee HAN
;
Jin Kyeoung KIM
;
Jin Yang JOO
;
Kyu Sung LEE
Author Information
1. Department of Neurosurgery, Pundang CHA Hospital, Pochon Medical University, Sungnam, Korea.
- Publication Type:Original Article
- Keywords:
Brain neoplasms;
Folic acid;
Methylenetetrahydrofolate reductase;
Polymorphism;
Risk factors
- MeSH:
Adult;
Alleles;
Brain Neoplasms*;
Brain*;
Case-Control Studies;
DNA;
DNA Methylation;
Folic Acid;
Genotype;
Glioma;
Humans;
Incidence;
Meningioma;
Metabolism;
Methylenetetrahydrofolate Reductase (NADPH2);
Neural Tube Defects;
Neurilemmoma;
Oxidoreductases*;
Risk Factors;
S-Adenosylmethionine;
Sample Size;
Vascular Diseases
- From:Journal of Korean Neurosurgical Society
2002;32(3):183-188
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Recent epidermiologic studies suggested that alterations in folate metabolism as a result of polymorphism in the enzyme 5,10-methylenetetrahydrofolate reductase(MTHFR) have been frequently associated with neural tube defects, vascular disease, and some cancers. A common 677C->T polymorphism in the MTHFR gene results in thermolability and reduced MTHFR activity that decreases the pool of 5-methyltetrahydrofolate and increases the pool of 5,10-methylenetetrahydrofolate. A possible cause underlying altered DNA methylation could be an insufficient level of S-adenosylmethionine as a consequence of weaker alleles of MTHFR gene. Therefore, the weak MTHFR activity may underlie susceptibility to brain neoplasms. We now report the associations of MTHFR polymorphisms in three groups of adult brain tumors: gliomas, meningiomas and schwannomas. METHODS: We analyzed DNA of 71 brain tumors and 254 age- and sex-matched controls with a case-control study. MTHFR variant alleles were determined by a PCR-restriction fragment length polymorphism assay. RESULTS: The incidence of the MTHFR 677TT genotype was higher among 20 schwannoma cases compared with that of 254 controls, conferring a 5-fold increase of the risk of schwannomas(odds ratio, OR=4.75 ; 95% confidence index, CI=1.05-21.50). The homozygous mutant group had half the risk of meningioma(OR=0.42:95% CI = 0.11-1.58) compared with the homozygous normal or heterozygous genotypes. There was no significant difference in MTHFR 677TT genotype frequency between glioma group(19 cases) and control group(254 cases)(OR = 1.53 ; 95% CI = 0.30-7.73). CONCLUSION: The data indicate that the homozygous 677TT MTHFR genotype confers the significantly higher risk of schwannoma and the lower risk of meningioma. However, our study had limited a statistical power because of the small sample size, which is reflected in the wide CIs. Hence, these findings need to be confirmed in larger populations.
